Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
144.98
+1.98 (1.38%)
At close: Sep 21, 2026, 4:00 PM EDT
144.98
0.00 (0.00%)
After-hours: Sep 21, 2026, 5:55 PM EDT
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $213.48M in the quarter ending June 30, 2026, with 3,749.17% growth. This brings the company's revenue in the last twelve months to $281.99M, up 34.81% year-over-year. In the year 2025, Protagonist Therapeutics had annual revenue of $46.02M, down -89.41%.
Revenue (ttm)
$281.99M
Revenue Growth
+34.81%
P/S Ratio
33.27
Revenue / Employee
$1,999,943
Employees
141
Market Cap
9.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.02M | -388.42M | -89.41% |
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 989.61M |
| TG Therapeutics | 799.54M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 440.48M |
| Twist Bioscience | 431.80M |
| ImmunityBio | 165.79M |
| Kymera Therapeutics | 105.00M |
| Cytokinetics | 67.67M |
PTGX News
- 11 days ago - Protagonist Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 12 days ago - Protagonist Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 13 days ago - Protagonist Therapeutics announces $300M share repurchase program - TheFly
- 13 days ago - Protagonist Therapeutics Announces $300 Million Share Repurchase Program - Accesswire
- 13 days ago - Protagonist Therapeutics Slides: Corporate presentation - Filings
- 19 days ago - Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 - Accesswire
- 20 days ago - Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital - TheFly
- 20 days ago - Protagonist Therapeutics price target raised to $180 from $153 at Barclays - TheFly